Faculty of Medicine
Permanent URI for this communityhttps://repository.ukim.mk/handle/20.500.12188/14
Browse
39 results
Search Results
- Some of the metrics are blocked by yourconsent settings
Item type:Publication, Regulating the future of laboratory medicine: European regulatory landscape of AI-driven medical device software in laboratory medicine(Walter de Gruyter GmbH, 2025-05-28) - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Linking inflammation and cardiovascular disease: the emerging role of lipoprotein-associated phosphoplipase A2(Ltd Chetverta Кhvylia, 2025-12); Over the past decades, inflammation has been recognized as a key contributor to the development of atherosclerosis, prompting extensive research. Numerous inflammatory markers have demonstrated predictive value for both initial and recurrent coronary events in individuals with or without established coronary vascular disease (CVD). Among these, lipo protein associated phospholipase A2 (Lp PLA2) has garnered significant attention. Lp PLA2 may be involved in the athero sclerotic process and contribute to plaque destabilization through its inflammatory activity within atherosclerotic lesions. Lipoprotein associated phospholipase A2 (Lp PLA2), a recently identified cardiovascular specific inflammatory mediator, is closely associated with the onset and progression of cardiovascular events. This review explores the potential of Lp PLA2 as both a risk marker and a therapeutic target in CVD. Elevated levels of Lp PLA2 mass and activity have been linked to an increased risk of CVD in both the general population and patients with pre existing disease. However, it remains uncer tain whether incorporating Lp PLA2 measurements into risk prediction models significantly enhances risk stratification beyond traditional cardiovascular risk factors. Additionally, the failure of darapladib, a potent and selective Lp PLA2 inhibitor, to reduce CVD events in major randomized, placebo controlled trials suggests the importance of ongoing research to fully understand its functions and develop effective strategies for CVD prevention and treatment. - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Serum amyloid A as a biomarker: diagnostic relevance and clinical association with acute ischemic stroke(MEDICAL FACULTY - SKOPJE, 2025-10-16); ; - Some of the metrics are blocked by yourconsent settings
Item type:Publication, COMPARATIVE ACCURACY OF LDL-CHOLESTEROL ESTIMATION: OMPARATIVE ACCURACY OF LDL-CHOLESTEROL ESTIMATION: A META-ANALYSIS OF THE FRIEDEWALD AND MARTIN-HOPKINS EQUATION META-ANALYSIS OF THE FRIEDEWALD AND MARTIN-HOPKINS EQUATION(Bulgarian Society of Cardiology and Pensoft Publishers, 2025-12-04) - Some of the metrics are blocked by yourconsent settings
Item type:Publication, BIOMARKERS IN OBESITY-RELATED METABOLIC SYNDROME: FROM PATHOPHYSIOLOGY TO CLINICAL APPLICATION(Macedonian Association of Anatomists and Morphologists, 2025-11-25) - Some of the metrics are blocked by yourconsent settings
Item type:Publication, MICROALBUMINURIA AS A POSSIBLE BIOMARKER IN EARLY DETECTION OF KIDNEY LESIONS IN PATIENTS WITH TYPE 2 DIABETES(Macedonian Association of Anatomists and Morphologists, 2025-05); ; ; ; Today, there is growing evidence supporting the association between renal failure and microalbumin (McA) concentration. The role of McA in the development of microcirculation damage in diabetic nephropathy (DN) has been proven. In our obsevational study were including 78 patients with type2 diabetes. The baseline level of McA showed to be significantly increased in patients with DN, and it was related to the severity of the renal disease. We were focusing on patients with a five-year-old diagnosis of diabetes mellitus type 2 (DM2). After their a two-year follow-up, we found that microalbumin in urine increased afther 6 mounths and one year in some of patients. Microalbumin was determined using of turbidimetric method in the laboratory of the Institute of Medical and Experimental Biochemistry. For serum creatinine, we were using a standardized enzyme method. MDRD4 formula was the best for calculation of glomerular filtration rate. A statistical analysis of the data was performed with the statistical program IBM SPSS 26 for Windows. The results obtained regarding albumin in urine showed: mean 42.04 mg/L, extremely high CV, and were in negative correlation with GFR. Using a multivariate linear regression model, we proved the fact that the increased McA level in the urine significantly influenced the decline of GFR. In patients with a high risk of developing diabetic nephropathy, appropriate measures were taken in order to register and prevent the disease on time. The large variability could be due to differences in disease progression among individuals since microalbuminuria is a marker of early kidney damage, besides other promoters of progression. - Some of the metrics are blocked by yourconsent settings
Item type:Publication, ROLE OF LIPOPROTEIN-ASSOCIATED PHOSPHOLIPASE A2 (LP-PLA2) IN THE PREDICTION AND ASSESSMENT OF THE SEVERITY OF CORONARY ARTERY DISEASE IN PATIENTS WITH TYPE 2 DIABETES MELLITUS(Society of Medical Biochemists of Serbia, Belgrade, 2025-05); ; ; Background: Lipoprotein-associated phospholipase A2 (LpPLA2) is a specific biomarker associated with an increased risk of coronary artery disease (CAD) development. This study aims to determine the relationship between Lp-PLA2 activity and the risk of development and severity of CAD in patients with type 2 Diabetes mellitus (T2DM). Methods: The cross-sectional study included 148 patients with T2DM, divided into two groups: patients with T2DM without confirmed CAD (n=56) and patients with T2DM and confirmed CAD (n=92), further divided into three subgroups based on the stage of CAD, and a control group of healthy individuals (n=44). Venous blood samples were collected from all participants to measure glucose, cholesterol, triglycerides, HDL, LDL, C-reactive protein, urea, and creatinine levels using standard photometric methods. LpPLA2 activity was measured using a chemiluminescent immunoassay method.Results: Patients with T2DM and confirmed CAD had significantly higher Lp-PLA2 levels than those without confirmed CAD and healthy individuals. A significant difference in LpPLA2 levels was found between the group without CAD, the patients with CAD divided into subgroups according to disease stage, and the healthy control group. A positive correlation was observed between Lp-PLA2 and BMI, glycated haemoglobin, total cholesterol, and HDL cholesterol. The optimal cutoff value for Lp-PLA2<250 ng/mL yielded a diagnostic sensitivity of 95.65% and specificity of 88.64% for patients with T2DM and diagnosed CAD. Conclusions: Lp-PLA2 can be used as a predictor for developing and assessing the severity of CAD in patients with T2DM. - Some of the metrics are blocked by yourconsent settings
Item type:Publication, EARLY URINARY MARKERS FOR RENAL INJURY IN OBESE CHILDREN AND ADOLESCENTS WITH OR WITHOUT INSULIN RESISTANCE(Walter De Gruyter, 2025-05); - Some of the metrics are blocked by yourconsent settings
Item type:Publication, CIRCULATING OXIDIZED LOW-DENSITY LIPOPROTEIN LEVELS IN AN EARLY STAGE OF ACUTE ISCHEMIC STROKE(Walter De Gruyter, 2025-05); ; ; - Some of the metrics are blocked by yourconsent settings
Item type:Publication, LIPOPROTEIN - ASSOCIATED PHOSPHOLIPASE A2 (LP-PLA2) LEVELS IN PATIENTS WITH DIABETIC NEPHROPATHY(Walter De Gruyter, 2025-05); ;